Journal
Pulmonary Circulation
Publication Date
4-2022
Volume
12
First Page
e12055
Document Type
Open Access Publication
DOI
10.1002/pul2.12055
Rights and Permissions
Rahaghi, FF, Balasubramanian, VP, Bourge, RC, Burger, CD, Chakinala, MM, Eggert, MS, Elwing, JM, Feldman, J, King, C, Klinger, JR, Mathai, SC, McConnell, JW, Palevsky, HI, Restrepo-Jaramillo, R, Safdar, Z, Sager, JS, Sood, N, Sulica, R, White, RJ, Hill, NS. Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat. Pulmonary Circulation. 2022; 12:e12055. doi.org/10.1002/pul2.12055 © 2022 The Authors. Pulmonary Circulation published by John Wiley & Sons Ltd on behalf of Pulmonary Vascular Research Institute. This is an open access article under the terms of the Creative Commons Attribution‐Non Commercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Recommended Citation
Rahaghi, Franck; Balasubramanian, Vijay; Bourge, Robert; Burger, Charles; Chakinala, Murali; Eggert, Michael; Elwing, Jean; Feldman, Jeremy; King, Christopher; Klinger, James; Mathai, Stephen; McConnell, John; Palevsky, Harold; Restrepo-Jaramillo, Ricardo; Safdar, Zeenat; Sager, Jeffrey; Sood, Namita; Sulica, Roxana; White, R. James; and Hill, Nicholas, "Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat." Pulmonary Circulation. 12, e12055 (2022).
https://digitalcommons.wustl.edu/open_access_pubs/11692
